ABNORMAL INTERLEUKIN 2 RECEPTOR EXPRESSION IN ADULT T CELL LEUKEMIA

Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

ABNORMAL INTERLEUKIN 2 RECEPTOR EXPRESSION IN ADULT T CELL LEUKEMIA

Interleukin 2. Smith KA, ed. New York, Academic, p. 179-96, 1988.. Unique Identifier : AIDSLINE ICDB/89656588
Uchiyama T; First Div., Dept. of Internal Medicine, Faculty of Medicine,; Kyoto Univ., Kyoto 606, Japan

Abstract: Interleukin 2 (IL-2), a polypeptide growth factor, was originally found as a T-cell growth-promoting factor. Specific binding sites for IL-2 were first demonstrated by a binding assay utilizing radiolabeled IL-2. Anti-Tac antibody was made by immunizing a mouse with T cells cultured with IL-2 from a patient with adult T-cell leukemia (ATL). Development of the anti-Tac monoclonal antibody, identification of anti-Tac antibody as an anti-IL-2 receptor antibody, characterization of IL-2 receptor (IL-2R), IL-2R expression in B cells, IL-2R expression in ATL, and human T-lymphotropic virus (HTLV) infection and IL-2R expression are described; and the possible role of IL-2R in the leukemogenesis and IL-2R expression in T-cell chronic lymphocytic leukemia are discussed. The anti-Tac antibody was shown to recognize human IL-2R by several pieces of evidence, including the inhibition of binding of IL-2, enabling cloning of the cDNA encoding the IL-2R. IL-2R is abnormally (constitutively) expressed on leukemic cells from ATL patients and cell line cells infected with HTLV-I, an etiologic agent of ATL. A hypothetical model of the leukemogenesis of ATL is presented that includes the following steps: (1) HTLV-I infection, (2) activation of the IL-2R gene, (3) constitutive expression of IL-2Rs, (4) polyclonal growth of T4(+) HTLV-I(+) cells through IL-2R (autocrine or paracrine), (5) selective and monoclonal growth of T4(+) HTLV-I(+) cells expressing IL-2Rs, and (6) development of ATL. (63 Refs)

Keywords: Antibodies, Monoclonal/DIAGNOSTIC USE Antibody Formation B-Lymphocytes/IMMUNOLOGY DNA/GENETICS Human Interferon Type II/PHARMACOLOGY Interleukin-2/GENETICS/*IMMUNOLOGY/PHARMACOLOGY Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/GENETICS/ *IMMUNOLOGY Leukemia, T-Cell, Acute/GENETICS/*IMMUNOLOGY Leukemia, T-Cell, Chronic/GENETICS/IMMUNOLOGY Protein Processing, Post-Translational Receptors, Interleukin-2/GENETICS/*IMMUNOLOGY MONOGRAPH REVIEW REVIEW, TUTORIAL

891130
M89B0599

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .